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Pediatric obesity is a growing national and global concern with nearly 1 in 5 
children in the U.S. affected [1].The American Academy of Pediatrics endorsed expert 
committee recommendations in 2007 to assist clinicians in pediatric weight management; 
however, adherence to these recommendations among primary care providers is 
suboptimal, and measuring adherence in feasible and pragmatic ways is challenging[2-4]. 
Commonly used quality measures that rely on billing data alone are an inadequate 
measure of provider attention to weight status in pediatric populations as they do not 
capture whether providers communicate about elevated body mass index (BMI) and 
associated medical risks with families. Electronic phenotyping is a unique tool that has 
the ability to use multiple areas of stored clinical data to group individuals according to 
pre-defined characteristics such as diagnostic codes, laboratory values or medications. 
We examined the external validity of a phenotyping algorithm, developed previously by 
Turer et al and validated in a single health system in Texas, that assesses pediatric 
providers’ attention to obesity and overweight using structured data from the electronic 
health record (EHR), to three pediatric primary care practices affiliated with Yale New 
Haven Health. Well child visit encounters were labeled either “no attention”, “attention to 
BMI only”, “attention to comorbidity only,” or “attention to BMI and comorbidity”. The 
performance of the algorithm was evaluated on the ability to predict “no attention”, using 
 iii 
chart review as the reference standard. The application of the minimally altered algorithm 
yielded a sensitivity of 94.0% and a specificity of 79.2% for predicting “no attention”, 
compared to a sensitivity of 97.9% and a specificity of 94.8% in the original study. Our 
findings suggest that while electronic phenotyping using structured EHR inputs provides 
a better evaluation of clinic encounters than use of diagnostic codes alone, methods that 
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1. Definitions of Pediatric Overweight and Obesity 
Overweight and obesity are clinical terms used to denote excess body weight, most 
frequently thought of in the form of adipose tissue. A commonly used measure for 
estimating body fat percentages in medicine is body mass index (BMI). BMI provides a 
measure of body weight adjusted for height, and although it does not provide a direct 
measure of body fat, levels do correlate with and are predictive of future adiposity [5]. 
BMI is also clinically useful as it can easily be assessed in the primary care setting with 
routine measurements of height and weight as opposed to more precise but less feasible 
methods such as dual-energy x-ray absorptiometry. Given the nature of the calculation, 
BMI may overestimate adiposity in children who have shorter statures or higher muscle 
mass and may underestimate adiposity in children with very low muscle mass. However, 
given its low cost, clinical utility and practicality, it is broadly used in clinical 
environments. It is therefore applied as an initial screen in assessing a patient’s risk for 
obesity and obesity-related comorbidities. Due to the fact that children’s BMI 
measurements change dramatically with age and differ with sex, age-and sex-specific 
BMI percentiles based on the Center for Disease Control (CDC) growth charts are used in 
place of raw BMI values[6]. Cutoff points for increased health risks are defined 
according to the 2007 expert committee recommendations convened by the department of 
Health and Human Services[5]. These guidelines suggest that a BMI of less than the 85th 
percentile is unlikely to pose health risk, whereas a BMI greater than or equal to the 95th 
percentile would confer significant risk. The terms “overweight” are therefore applied to 
a BMI ³ 85th percentile and “obesity” to a BMI ³ the 95th percentile. While the CDC 
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growth charts are useful for a large percentage of patients with overweight and obesity, 
BMI percentiles beyond the 97th percentile are not clinically useful, as large changes in 
BMI result in small percentile changes at the extreme. Therefore an additional metric, 
percentage of BMI at the 95th percentile (%BMIp95), is used to better assess and follow 
patients with severe obesity, defined as a BMI greater than or equal to 120% of the 95th 
percentile for age and sex[7].  
2. What Does Pediatric Obesity and Overweight look like in the US? 
  On a population level, obesity disproportionately affects children from 
racial/ethnic minority backgrounds. African-American and Latino children display higher 
BMI scores from a young age and maintain a higher BMI growth trajectory compared to 
their non-Hispanic White counterparts [8]. According to some studies looking at 
disparities in obesity prevalence, obesity seems to emerge and is sustained earlier in 
Hispanic children relative to African Americans, but both groups experience higher BMIs 
by the 8th grade relative to non-Hispanic White children[9]. The morbidities associated 
obesity, such as hypertension and type II diabetes, are also disproportionately diagnosed 
in minority children and tend to be seen more in boys [10]. Having diseases such as 
elevated blood pressure or diabetes in childhood confers further risk of these diseases 
carrying on into adulthood and increases overall risk of mortality from cardiovascular or 
metabolic diseases [10, 11].  
The risk factors associated with obesity are complex and intertwined.  In general, 
poverty is positively associated with obesity prevalence[5]. There is evidence that genes 
play a role in obesity risk, and having one or both parents with obesity, increases the risk 
of a child developing obesity significantly [12]. However, the rapid increase in 
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prevalence at a population level suggests that environmental factors play a greater role 
than genetic shifts in the population[11]. Many associations with obesity risk such as 
infant birth weight, increased screen time, sleep patterns, and neighborhood-level factors 
have been described, but their interdependence and individual contribution to a patient’s 
risk are largely undefined, making prediction, and prevention particularly difficult[6, 13-
16].  
Childhood obesity and overweight have shown to be predictors of future obesity, 
putting patients at risk for the eventual development of obesity-related comorbidities.[17] 
The medical complications of obesity are far reaching and include a range of life altering 
disorders including hypertension, diabetes mellitus, non-alcoholic fatty liver disease, 
dyslipidemia, asthma, and sleep apnea[18]. Managing these co-morbidities incur 
significant cost to individual patients and healthcare systems. One study estimates the 
lifetime cost for elementary students aged 6-11 with obesity to be $31,869 for boys and 
$39,815 for girls due mainly to the care required for comorbidity management [19].   
3. Current Guidelines on Addressing Pediatric Obesity  
In 2007, an expert committee was formed to revise the 1998 recommendations on 
childhood obesity. The recommendations were rooted in the latest evidence-based data 
and the experience of clinical experts to address prevention, assessment, and treatment of 
childhood overweight and obesity. The guidelines suggest that all children ages 2 years 
and older be screened with initial BMI measurements, family history of obesity and 
obesity-related disorders, and current diet and lifestyle practices. If a patient has a BMI 
that is ≥85th percentile, the first steps a provider should take are to assess the medical and 
behavioral risks of the individual patient. Medical risk assessment includes screening for 
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common comorbid conditions such as hypertension, type 2 diabetes, hyperlipidemia, and 
non-alcoholic fatty liver disease. It was recommended by the committee that laboratory 
tests to screen for and diagnose such conditions be conducted every 2 years for children 
ages 10 years and older with obesity (or with overweight if they have associated risk 
factors) [5].  Behavioral assessment includes identifying obesogenic behaviors such as 
elevated screen time, fast food consumption, sugar-sweetened beverage intake, and 
sedentary lifestyle. Providers should then take steps to address overweight and obesity, 
and the guidelines make suggestions of four different treatment stages. These stages are: 
stage 1 prevention plus, stage 2 structured weight management, stage 3 comprehensive 
multidisciplinary approach and stage 4 tertiary care intervention. Each stage builds from 
office-based counseling for lifestyle and family recommendations (stage 1) to nutrition 
and psychological counseling (stages 2 and 3). Stage 4 uses interventions such as 
medications, very low calorie diets, and bariatric surgery[5].  In cases of a child not 
reaching a desired weight goal or in the presence of significant comorbidities, 
pharmacotherapy can be considered. Orlistat is the only FDA approved medication for 
the treatment of overweight and obesity in adolescents. Moderate improvements in BMI 
have been associated with the use of Orlistat however, unlike in adult counterparts, 
improvement in lipids or insulin sensitivity have not been consistently shown. Metformin 
has also shown some ability to improve BMI in some short-term obesity studies when 
used in conjunction with lifestyle modifications. Reported results on lipid and insulin 
sensitivity have been variable and Metformin is not FDA approved for weight reduction 
in pediatric patients [20]. 
4. Current Practice vs. Guidelines 
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Pediatric primary care providers (PCPs) are the cornerstone of addressing 
pediatric obesity as many successful interventions rely on PCPs to screen for and manage 
children with elevated BMI [21, 22]. Studies report that patients and families see their 
primary care provider as a reliable source of information and their recommendations have 
positive impacts on weight management [23, 24]. However, suboptimal rates of diagnosis 
of overweight and obesity based on BMI percentile in pediatric primary care persist [25, 
26]. One 2011 study based on self-reported practice, found that less than 50% of primary 
care providers assessed BMI regularly in children and 58% reported rarely, or only 
sometimes using BMI percentiles to track weight [27]. Another 2011 study, found that 
pediatric providers reported unfamiliarity with the 2007 practice guidelines and 
diagnostic criteria for overweight and obesity suggesting that uptake of new practices has 
been slow[28]. Use of the Electronic Health Record (EHR) imparts the ability to auto-
calculate BMI percentiles theoretically improving provider attention and diagnosis. Yet, 
despite some improvement with broad implementations of the EHR, children with 
overweight and obesity are still underdiagnosed[25, 29]. Counseling behaviors amongst 
providers have also been shown to be variable depending on factors such as sex, personal 
beliefs and attitudes[25].  In particular, younger children (2-5 years old) and children 
with overweight are more likely to be underdiagnosed, not receive diet and exercise 
counseling and have an absence of screening studies [2, 25, 30].  Perceived barriers to 
providing adequate care are often reported to be the sensitivity of the topic, clinic time 
constraints, and feelings of futility [3, 31, 32]. These inconsistencies across providers 
present missed opportunities to engage with families early, influence BMI trajectories, 
and provide high-quality care.  
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5. Methods of Assessing Provider Attention to Pediatric Weight Status 
Given the growing need for PCP attention to childhood obesity and the 
suboptimal rates of diagnosis and screening, it is important to identify methods to support 
clinicians in this task. Broad use of the EHR puts researchers in a position to easily 
collect large amounts of data regarding physician practice. While manual chart review is 
still widely done, the process is laborious and may often limit sample sizes. Electronic 
phenotyping involves automated identification of subjects based on exclusion and 
inclusion criteria present in stored clinical data. Electronic phenotyping is typically used 
to identify patients with certain characteristics for a given purpose i.e.; a clinical trial, or 
retrospective study.  In a study published in 2018 titled, “Algorithm to detect pediatric 
provider attention to high BMI and associated medical risk,” Dr. Christy Turer and 
colleagues developed an electronic phenotyping algorithm using extractable EHR 
variables to indicate adherence to the 2007 expert committee guidelines on childhood 
obesity. Using diagnostic codes, laboratory studies, referrals, medications and procedures 
they categorized provider behavior in response to elevated BMI measurements into one 
of three phenotypes: “no attention”, attention to “BMI Alone”, and attention to 
“BMI/Medical Risk”.  Validation of the performance of the electronic phenotypes using 
manual chart review showed excellent sensitivity and specificity to detect provider 
attention types in pediatric clinics in Dallas, Texas[33]. By employing an algorithm to 
evaluate clinician behavior, Turer et al created a tool that went beyond identifying 
patients with disease characteristics to identifying encounters that follow guideline-based 
care. Furthermore, a follow up study published in 2019 by Turer et. al, demonstrated that 
children categorized by the algorithm as having primary care visits with attention to 
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elevated BMI and/or obesity-related medical risk were more likely to have improvement 
in weight status at follow-up visits [34]. Based on the results of these studies out of Texas 
and the anticipated benefits of using electronic phenotypes to augment provider practices, 
we sought to replicate and externally validate the Turer algorithm[33] in the Yale New 




STATEMENT OF PURPOSE 
 
Hypothesis: We anticipate that the algorithm developed by Turer et. al 2018 to identify 
attention to elevated BMI and weight-related comorbidities among pediatric primary care 
clinicians would be applicable to 6-12 year-old children with overweight/obesity, defined 
as a BMI ≥85th percentile, seen for well child visits in Yale New Haven Health pediatric 
primary care practices. Specifically, we hypothesize that implementation of this 
algorithm among patients at Yale-affiliated practices will yield a sensitivity and 
specificity for predicting attention (per manual review of EHR documentation) that are 
similar to the Turer study at a health system in Dallas, Texas. We also anticipate, based 
on data from previous research, that children with obesity or severe obesity will be more 
likely to be assigned an attention category in comparison to children with overweight, 
and non-Hispanic Black and Hispanic children will be more likely to be assigned an 
attention category than their non-Hispanic White counterparts [2, 25, 30, 35]. We expect 
to see variations on clinical practice based on trainee level as has been documented 
previously and therefore predict that children with encounters in the summer months 
(July- September), when new physicians begin their residency training,  will be more 
likely to receive “no attention” than children seen later in other months [28, 36, 37].  
Lastly, we predict that children with public versus private health care payors will be more 
likely to receive higher levels of attention. 
Specific Aim 1: To externally validate the algorithm described by Turer et. al 2018 
among 6-12 year old children with overweight/obesity seen at the Yale New Haven 
Hospital-affiliated pediatric primary care practices.  
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Specific Aim 2: To examine associations between pediatric provider attention and 1) 
weight category (overweight, obesity, severe obesity), 2) insurance type, 3) race/ethnicity 






Data Source:  
We examined the records of 300 randomly selected patients ages 6-12 with two or 
more measurements of elevated BMI percentiles (³85th percentile) for age and sex who 
were seen for well child visits on two or more occasions at any one of three pediatric 
primary care practices in the Yale New Haven Health system: the Yale Pediatric Primary 
Care Clinic (PCC), Yale Health Center (YHC), and Saint Raphael Campus Primary Care 
Clinic (SRC) from June 1, 2018 to May 31, 2019. If multiple encounters for the same 
patient occurred within that time period, we examined the encounter from the first 
chronological date. We categorized children’s weight status based on the Center for 
Disease Control (CDC) growth charts from 2000 which classifies BMI-for-age into the 
following categories stratified by sex: overweight ³ 85th  to < 95th percentile, and obesity 
³95th percentile[38]. The intention of this study was to only examine patients with 
overweight or obesity.  
Exclusion Criteria:  
Patients were excluded from the study if they had less than two recorded BMI 
measurements above the 85th percentile to ensure that we were not examining visits with 
aberrant or incorrect BMI recordings. We also excluded children that were taking 
medications or had conditions that impact growth and nutrition (e.g., pregnancy, thyroid 
dysfunction, growth hormone abnormalities and sex hormone abnormalities).  
Measures and Data Collection:  
We extracted the following variables from the medical records of eligible patients:  
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a.  Visit and problem list diagnosis codes entered on the date of the 
encounter  
b. Referrals entered on the date of the encounter  
c. Procedures/ lab orders entered on the date of the encounter  
d. Medication lists queried for prescriptions written on day of the encounter 
e. Age calculated in months based off of patient’s birthdate and age at visit 
f. BMI calculated using height and weight on the date of the visit  
g. BMI categorization defined as overweight (≥85th – < 95th percentile), 
obese (≥95th - <120% of the 95th percentile) and severely obese (>120% of the 
95th percentile) using CDC growth charts BMI for age.   
h. Sex (Male or Female)  
i. Race/ethnicity defined as non-Hispanic Black, non- Hispanic White, 
Hispanic and Asian.  
j. Insurance type defined as public (Medicaid), private (Blue Cross Blue 
Shield, Managed, or other commercial insurance), and Uninsured (self-pay or 
missing)  
k. Provider type: defined as Nurse Practitioner, Physician Assistant, 
Physician (Attendings and Fellows), and Resident 
Construction and Implementation of Algorithm to Detect Provider Attention: 
 The algorithm was modeled after the electronic phenotype described by Turer et. 
al[33]. After collecting the diagnostic codes, laboratory studies, medications, procedures 
and referrals used by our cohort, patient visits were classified into the following broad 
attention types: No Attention, Attention to BMI alone, Attention to Comorbidities alone, 
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and Attention to BMI and Comorbidities. The cohort was then sub-classified into 
comorbidity subtypes (Attention to Diabetes, Attention to Fatty Liver Disease, Attention 
to Hyperlipidemia and Attention to Vitamin D Deficiency) based on criteria listed by 
Turer et al (Figure 1). Criteria for classifying visits into attention types are listed in Table 
1 for broad categories and Table 2 for comorbidity sub-types. The criteria were defined 
by reviewing the diagnostic codes, laboratory studies, medications, referrals and 
procedures used by Turer’s team and comparing them to the corresponding values used in 
our population. Given that the original study was conducted using ICD-9 diagnostic 


















Table 1. Diagnostic codes, laboratory studies, referrals and procedures that were used to qualify for each attention type 




















E66.09 Obesity due to excess calories, unspecified 
obesity severity 
E66.09, Z68.54 Obesity due to excess calories 
without serious comorbidity with body mass index 
(BMI) in 95th to 98th percentile for age in 
pediatric patient 
E66.3 Overweight 
E66.3, Z68.53 Overweight peds (BMI 85-94.9 
percentile) 
E66.3, Z68.54 Body mass index (BMI) of 95th to 
99th percentile for age in pediatric patient 
E66.9 Obesity (BMI 30-39.9)/Obesity, unspecified 
classification, unspecified obesity type, 
unspecified whether serious comorbidity present 
E66.9, Z68.53 Obesity, pediatric, BMI 85th to less 
than 95th percentile for age 
E66.9, Z68.54 Obesity peds (BMI >=95 
percentile)/BMI (body mass index), pediatric 95-
99% for age, obese child structured weight 
management/multidisciplinary intervention 
category 
R63.3 Feeding difficulties 
R63.5 Weight gain/abnormal weight gain 
Z68.41BMI 40.0-44.9, adult (HC Code) 
Z68.53 BMI (body mass index), pediatric, 85% to 
less than 95% for age 
Z68.54 BMI pediatric, greater than or equal to 
95% for age 
Z71.3 Nutritional counseling 
Z72.4 Inappropriate diet and eating habits 
 
Orlistat  
DNA methylation analysis for 
Angelman or Prader Willi 
Syndrome  
Mutation analysis for Angelman or 
Prader Willi Syndrome  
*No patients in our population were 
taking medicines to treat obesity 
*No patients in our population had 
lab studies for Angelman, Prader 
Willi syndrome targeted gene 
mutation analysis or DNA 















Attention to BMI and 
Comorbidity  
³1 diagnosis code for BMI and ³1 diagnosis code 
for: 
• Elevated blood pressure/hypertension 
• Acanthosis, prediabetes, diabetes type 2 
• Lipid disorders 
• Fatty liver disease 
• Vitamin D deficiency 
*See table 2 for codes broken up by comorbidity  
 
Labs to screen for diabetes, lipid 
disorders, fatty liver disease, or 
vitamin D deficiency (2 lab orders 
required, because increased 
likelihood lab ordered to screen 
for comorbidities related 
to overweight/obesity) 
• Medicines to treat hypertension, 
diabetes, lipid disorders, or 
vitamin D deficiency 
 
*See table 2 for laboratory studies 

















Comorbidity Alone  
³1 diagnosis code for: 
• Elevated blood pressure/hypertension 
• Acanthosis, prediabetes, diabetes type 2 
• Lipid disorders 
• Fatty liver disease 
• Vitamin D deficiency 
*See table 2 for codes broken up by comorbidity  
 
Labs to screen for diabetes, lipid 
disorders, fatty liver disease, or 
vitamin D deficiency (2 lab orders 
required, because increased 
likelihood lab ordered to screen 
for comorbidities related 
to overweight/obesity) 
• Medicines to treat hypertension, 
diabetes, lipid disorders, or 
vitamin D deficiency 
 
*See table 2 for laboratory studies 






















Figure 1: Overview of how attention types are assigned based on EHR collected variables. Please see Table 1 for 











Diagnosis Codes Referrals Laboratory Studies Medicines 
 
 
Attention to Hypertension  
R03.0: Elevated BP without 
diagnosis of hypertension/single 
episode of elevated blood 







*No lab orders were used in 












Attention to Diabetes  
E11.65: Uncontrolled type 2 
diabetes mellitus without 
complication, without long-term 
current use of insulin 
L83: Acanthosis Nigricans 
R73.03: Attention to Diabetes 
R73.09: Elevated hemoglobin 
A1c 








Glucose, fasting  
Glucose, gray top  
HEMOGLOBINA1C 
Insulin, total (BH GH LMW Q 
YH) 































LIPID PANEL WITH 
LDL/HDL RATIO (L) 
atorvastatin  
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Attention to Fatty Liver 
Disease  
R74.0: Elevated ALT 
measurement 
R74.8: Elevated liver enzymes 







Hepatic function panel 
Hepatic function panel (LFT) 
LIVER FUNCTION TESTS 
(YH) 
Comprehensive metabolic panel 
Comprehensive metabolic panel 






Attention to Vitamin D 
Deficiency 
E55.9: Vitamin D deficiency 
 
 QuestAssureD 25-OH vitamin 
D, (D2,D3), LC/MS/MS (LMW 
Q) 
QuestAssureD 25-OH vitamin 
D, (D2,D3), LC/MS/MS (BH 
LMW Q) 
VITAMIN D, 25-HYDROXY, 
TOTAL (GH L) 
Vitamin D 25 hydroxy (BH 
LMW) 
Vitamin D, 25-hydroxy, 





Table 2: Values used to qualify for attention to each comorbidity subtype based on data from our Yale associated 
practices. 
 
Reference Standard:  
 To evaluate the performance of the electronic phenotype, an independent chart 
review process was done to validate the algorithm’s ability to detect “No Attention”. The 
dual purpose of the review was to manually examine the values used by the algorithm 
(diagnostic codes, labs, etc.) and to inquiry the visit encounter for other evidence of 
attention for which the algorithm was not designed to detect such as written text, or 
media entries. This process was done with substantial input from Dr. Christy Turer and 
attempts were made to maintain fidelity between the chart review she conducted and 
ours.  
 We began by examining the chart review/abstraction guide and questionnaire used 
in the Turer et al 2018 study to review 300 charts. We first converted her questionnaire 
from a paper copy to an online version in Qualtrics™ survey software (Qualtrics, Provo, 
UT). Several questions in the original questionnaire were intended to collect data for 
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other projects and were thus eliminated from our survey. Given that there are institutional 
differences in EPIC layout and note templates, our chart review guide had to be adapted 
to give clear directions for how to locate the desired information. In conjunction with Dr. 
Turer and in effort to replicate her team’s process as much as possible, we also modified 
and added questions to the chart abstraction questionnaire to improve clarity and 
completeness. Examples of this include looking for laboratory orders in addition to 
laboratory results and adding a question to manually look at visit and problem list 
diagnostic codes associated with an encounter. Chart reviews included reviewing the 
growth chart, problem list, medication list, laboratory studies, family history, externally 
uploaded media, and visit notes associated with the visit date for each patient. Each chart 
was reviewed systematically using the Qualtrics survey. We used two separate reviewers 
(AG, AF) to examine 30 charts (10% of total) and compared responses to each Qualtrics 
survey question. Discrepancies in the responses were resolved with either a third-party 
reviewer (MS) or direct discussion between the reviewers. Interrater reliability was 
measured using the kappa statistic and interpreted using the guidelines outlined by Koch 
and Landis[39].  
 A difference in our chart review process in comparison to the original project was 
the selection of charts. Dr. Turer’s team randomly selected 100 charts from each attention 
type (No Attention, Attention to BMI, Attention to Comorbidity). To control for bias, we 
chose to blindly review 300 charts from the cohort of 6-12 year olds and compare 
assigned attention types after completion of the review.   
Statistical Analysis:  
Our primary outcome was the algorithm’s sensitivity and specificity of predicting 
no attention versus any attention compared to the reference standard. 
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 The secondary analysis looked at demographic differences between attention 
types (no attention, attention to BMI alone, attention to Comorbidities alone, and 
attention to BMI and Comorbidities), for both chart review and algorithm, using Chi-
squared tests of association. 
 Kappa statistics were computed by hand for interrater reliability (n = 2) of the 
chart review. All other analyses was completed using SAS version 9.4 (SAS Institute, 
Cary, NC).  
Responsibilities: 
The thesis primary author (AGB) was responsible for IRB writing and approval 
(with oversight from Dr. Sharifi), data randomization, creation of the chart review tool 
and review of clinic encounters. Kaitlin Maciejewski, MS (biostatistician) developed the 
SAS code to implement the algorithm and to conduct the statistical analysis. Additional 
support clarifying which variables were included in the original algorithm in Texas and 
general guidance was provided by Christy Boling Turer MD, MHS. Ada Fenick, MD 
assisted with the duplicate review of 10% of clinical encounters and helped refine the 




We reviewed 329 charts to identify 300 encounters that met our inclusion criteria 
and excluded 29 charts due to BMI measurements not meeting inclusion criteria. The 
mean±SD age of the sample was 10±1.87 years and 58.3% of children were male. Table 
3 displays the demographics and encounter characteristics of the sample. In terms of 
weight categorization, 15.3% met criteria for severe obesity defined as ≥120% of 95th 
percentile, 41.3% met criteria for obesity, and 43.3% met criteria for overweight. The 
most prevalent race/ethnicity was Hispanic/Latino, compromising 42.7% of the cohort, 
Non-Hispanic Black was the next most prevalent 31% followed by Non-Hispanic White 
(15%) and Asian/Other (11.3%). Of the clinics included in our cohort, the majority (63.7 
%) of encounters were conducted at the PCC, 24.7% at YHC, and 11.7% at SRC. The 
majority of patients in our sample had a public insurance payor type (64.7%) and the 
remainder had a private payor (14.3%) such as a managed healthcare or “Blue-cross 
Blue-shield,” or other means (20.7%). Of the visit encounters examined, 49% were 
conducted by resident physicians with attending supervision, 25% by nurse Practitioners, 
17.3% by attendings and 8.3% by physician assistants.  
Table 5 displays the prevalence of attention to BMI and/or obesity-related 
comorbidities stratified by demographic and encounter characteristics. We observed 
statistically significant differences in the likelihood of classification as “no attention” by 
BMI category (p<0.001 for chart review and p<0.001 for algorithm) and by clinician type 
(p<0.001 for chart review and p<0.001 for algorithm). We did not observe statistically 
significant differences by race/ethnicity, season of encounter or insurance type.    
Validation of the Algorithm:  
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Of the 30 charts comprehensively reviewed by two reviewers (AG and AF), 
kappa scores suggested substantial inter-observer agreement: 0.697 (95% confidence 
interval 0.482-0.912). Of the 300 charts reviewed in total, 50 were assigned no attention 
by chart review compared to 99 assigned no attention by the algorithm. Chart review 
identified 102 charts as attention to BMI, 4 as attention to comorbidity alone, and 144 as 
attention to BMI and Comorbidity. The algorithm correctly identified 66 and 82 as 
Attention to BMI and Attention to BMI and Comorbidity, respectively. This yielded a 
sensitivity of 94.0%, specificity of 79.2%, positive predictive value 47.5%, and negative 
predictive value 98.5% (Table 4).   
A review of the charts for which the algorithm incorrectly labeled the encounter 
as “no attention,” the discordance between the algorithm and chart review was due to 
evidence of attention in the form of free text within the progress note. Of the 52 
encounters incorrectly labeled as no attention” by the algorithm, 83% had evidence of 
documentation in the assessment and plan and 49% had evidence of attention in the 
subjective sections of the progress note.  A few encounters were incorrectly labeled as 
attention by the algorithm due to the use of qualifying laboratory studies, diagnosis 
codes, or referrals but not in the context of weight management. For example, in one 
encounter the provider ordered screening lipids as part of routine care during a 10 year-
old’s well child visit in addition to vitamin D screening as part of deficiency screening in 
refugee clinic; these two lab orders satisfy the algorithm’s categorization of “attention to 
comorbidity” but were appropriately not identified as attention during chart review. 





Characteristic Overall Sample N (%) 
BMI categorization 
Overweight 130 (43.3%) 
Obesity (Class 1 only) 124 (41.3%) 
Severe Obesity (Class 2 and 3) 046 (15.3%) 
Race/ethnicity 
Asian/Other 033 (11.0%) 
Hispanic or Latino 128 (42.7%) 
Non-Hispanic Black 094 (31.3%) 
Non-Hispanic White 045 (15.0%) 
Provider type 
Attending 053 (17.7%) 
Nurse Practitioner 075 (25.0%) 
Physician Assistant 025 (08.3%) 
Resident 147 (49.0%) 
Season 
Fall 072 (24.0%) 
Spring 062 (20.7%) 
Summer 106 (35.3%) 
Winter 060 (20.0%) 
Insurance type 
Private Health care 044 (14.7%) 
Public health care 194 (64.7%) 
Other / missing 062 (20.7%) 
Clinic 
SRC 035 (11.7%) 
YHC (pediatrics) 074 (24.7%) 
YNH-PCC 191 (63.7%) 
Table 3 Demographics of the sample of 300 encounters examined. Obesity class 1 was defined as BMI percentile ³ 95th 









Chart review attention 
type 











Attention to BMI 66 2 0 34 102 
Attention to BMI 
 and Comorbidity 27 82 18 17 144 
Comorbidities only 0 0 3 1 4 
No attention 0 0 3 47 50 
Total 93 84 24 99 300 
Table 4: Comparison of algorithm and chart review attention assignments 
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Chart-Review Defined Algorithm Defined 
Attention to 


















Overweight 095 (38.0%) 035 (70.0%) 
<0.001 
070 (34.8%) 060 (60.6%) 
<0.001 
Obesity (class 
1 only)  110 (44.0%) 014 (28.0%) 093 (46.3%) 031 (31.3%) 
Severe 
Obesity (class 
2 and 3) 
045 (18.0%) 001 (02.0%) 038 (18.9%) 008 (08.1%) 
Race/ethnicity 
Asian/Other 030 (12.0%) 003 (06.0%) 
0.19 
025 (12.4%) 008 (08.1%) 
0.47 
Hispanic or 
Latino 108 (43.2%) 020 (40.0%) 088 (43.8%) 040 (40.4%) 
Non-Hispanic 
Black 079 (31.6%) 015 (30.0%) 058 (28.9%) 036 (36.4%) 
Non-Hispanic 
White 033 (13.2%) 012 (24.0%) 030 (14.9%) 015 (15.2%) 
Provider type 
Attending 050 (20.0%) 003 (06.0%) 
<0.001 
040 (19.9%) 013 (13.1%) 
<0.001 
Nurse 
Practitioner 052 (20.8%) 023 (46.0%) 040 (19.9%) 035 (35.4%) 
Physician 
Assistant 008 (03.2%) 017 (34.0%) 005 (02.5%) 020 (20.2%) 
Resident 140 (56.0%) 007 (14.0%) 116 (57.7%) 031 (31.3%) 
Season 
Fall 061 (24.4%) 011 (22.0%) 
0.75 
046 (22.9%) 026 (26.3%) 
0.83 Spring 054 (21.6%) 008 (16.0%) 040 (19.9%) 022 (22.2%) Summer 086 (34.4%) 020 (40.0%) 073 (36.3%) 033 (33.3%) 
Winter 049 (19.6%) 011 (22.0%) 042 (20.9%) 018 (18.2%) 
Insurance type 
Private Health 
care 038 (15.2%) 006 (12.0%) 
0.68 
030 (14.9%) 014 (14.1%) 
0.06 Public health care 159 (63.6%) 035 (70.0%) 122 (60.7%) 072 (72.7%) 
Other / 
missing 053 (21.2%) 009 (18.0%) 049 (24.4%) 013 (13.1%) 
Clinic 
SRC 016 (06.4%) 019 (38.0%) 
<0.001 
012 (06.0%) 023 (23.2%) 
<0.001 YHC (pediatrics) 063 (25.2%) 011 (22.0%) 053 (26.4%) 021 (21.2%) 
YNH-PCC 171 (68.4%) 020 (40.0%) 136 (67.7%) 055 (55.6%) 
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The purpose of this project was to assess the external validity of an electronic 
phenotyping algorithm that evaluates clinician attention to elevated BMI and associated 
comorbidities during pediatric primary care visits against a reference standard of manual 
chart review. Our chart review revealed that 250 out of 300 encounters (83%) had some 
evidence of attention to weight status or weight-related comorbidities in the electronic 
record associated with the visit, and 50 of the 300 (16%) encounters examined lacked 
evidence of any attention. The electronic phenotyping algorithm flagged 201 out of 300 
(67%) visits with an attention type (attention to BMI, attention to comorbidity or 
attention to BMI and comorbidity) and 99 out of 300 (33%) visits with no evidence of 
attention. The application of the Turer algorithm to the Yale pediatric primary care 
setting had a sensitivity of 94.0% and a specificity of 79.2% for predicting “no attention” 
versus any attention type. The positive predictive value of “no attention” relative to any 
attention type in our cohort was 47.5% and the negative predictive value of “no attention” 
was 98.5%. When examining the encounters labeled as “no attention”, we found 
significant differences in assignment based on weight category, consistent with previous 
research [2, 25, 30], as well as by clinician type.  
In comparison with the performance of the phenotyping algorithm in the original 
Turer et al study population, our algorithm had a slightly lower sensitivity and 
substantially lower specificity for identifying “no attention”. Using the sensitivity and 
specificity from the Turer et. al, study we would expect a positive predictive value of 
79.0% in our sample. However, our minimally modified algorithm yielded a positive 
predictive value of 47.5%.  The suboptimal specificity and positive predictive value could 
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be explained by a lack of generalizability of the original algorithm. The algorithm 
developed by Turer et al was refined based on the practices of documentation conducted 
at the UT Southwestern clinic sites. Several iterations of code were reviewed to enhance 
the performance of the algorithm in their practices. However, documentation practices 
regarding the structured inputs that the algorithm evaluated such as problem list entry or 
ICD 10 codes vary between sites. An example of this could be seen in the ordering of 
Vitamin D labs and the reporting of Vitamin D Deficiency. Vitamin D deficiency has 
been known to be associated with overweight/obesity and was included in the Turer 
algorithm as an indicator of attention to weight status. However, Vitamin D deficiency is 
routinely evaluated in the relatively large population of refugee patients seen at the Yale 
PCC, regardless of weight status, causing the algorithm to incorrectly identify attention to 
a comorbidity (false positives) and limiting the generalizability of the algorithm to the 
Yale primary care setting.  
Although our electronic phenotype had a lower sensitivity and specificity than the 
original study, its use of multiple EHR inputs make it a better predictor of attention than 
ICD diagnosis codes alone. For example, compared to a study completed at Yale 
pediatric primary care sites between November 2011 and May 2015, only 11% of 
children with overweight had a visit diagnoses of overweight in their medical record, 
37% of children with obesity has a diagnosis code, and 54% of children with severe 
obesity received had the corresponding  diagnosis code [35]. Other studies examining the 
use of diagnosis codes for overweight and obesity, have shown similarly low rates[2, 40, 
41]. This suggests that while diagnosis of obesity or overweight may still be sub-optimal, 
clinicians may be using other areas of the EHR to denote attention to weight status and 
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weight related comorbidities in their patients. Evaluating provider behavior solely on 
diagnosis codes provides an incomplete assessment of the clinic encounter.  
Although a substantial improvement over diagnosis codes alone, the Turer 
algorithm is limited to structured data and does not utilize the large amount of 
unstructured data available in EHR encounter, i.e, free text in clinical notes. It has already 
been established that clinicians have suboptimal rates of entering diagnosis codes and 
problem list entries. However, the clinical progress note is an important medical-legal 
document that many providers rely on to communicate information. We found that of the 
encounters that were incorrectly labeled as no attention” by the algorithm, a large 
percentage of them (83%) had evidence of documentation in the assessment and plan 
and/or in the subjective sections (49%) of the progress note. By excluding free-text 
elements in the clinical progress note from our evaluation of a clinical encounter, we are 
capturing an incomplete picture of the encounter. Future studies looking to continue use 
of electronic phenotyping to assess provider behavior should include natural language 
processing to capture unstructured EHR inputs.  
 Another limitation of this study is that it primarily evaluated the algorithm in 
mostly academic primary care settings. Although one of our study sites was a non-
teaching clinical environment, it is still difficult to predict performance in different 
settings such as private practices.  
  
In conclusion, our findings suggest that implementation of an electronic 
phenotyping algorithm without adaption for the local site may result in lower specificity 
than originally reported out of the health system in which the algorithm was developed. 
Although still clinically useful and superior to other available options, adaptions such as 
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the use of natural language processing could enhance the precision and accuracy of this 
phenotyping algorithm as a pragmatic tool to detect attention to elevated BMI and 
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